Currently Available Treatment Options for Relapsed/Refractory Multiple Myeloma

Anito-cel produced no delayed or non–immune effector cell–associated neurotoxicity syndrome among patients with multiple myeloma.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

During the 2024 IMS conference, teams from Cleveland, Ohio, and New York, New York, met to debate the latest advances in multiple myeloma.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Experts in multiple myeloma spoke about optimal treatment strategies for patients who receive bispecific therapy, focusing specifically on facilitating a multifaceted approach between academic and community practices.

An isatuximab-based quadruplet yields significant long-term benefits regardless of subsequent maintenance in in patients with transplant-eligible NDMM.